@alliance-org.bsky.socialDiscover the latest advances in breast, lung & prostate cancer care! Join the Alliance for a free public webinar on Oct 1 featuring leading researchers & patient advocates sharing key findings from #ASCO26. Register now: bit.ly/Alliance-Webinar-Oct26 #clinicaltrials
@alliance-org.bsky.socialDiscover the latest advances in breast, lung & prostate cancer care! Join the Alliance for a free public webinar on Oct 1 featuring leading researchers & patient advocates sharing key findings from #ASCO26. Register now: bit.ly/Alliance-Webinar-Oct26 #clinicaltrials
@artera.aiAt #ASCO26, Xinglei Shen, MD, discussed new research evaluating Artera’s multimodal AI biomarker in a real-world population, along with findings from a new image-only model for localized #ProstateCancer.
Watch the conversation: buff.ly/aKYVlmp
@alliance-org.bsky.socialDiscover the latest advances in breast, lung & prostate cancer care! Join the Alliance for a free public webinar on Oct 1 featuring leading researchers & patient advocates sharing key findings from #ASCO26. Register now: bit.ly/Alliance-Webinar-Oct26 #clinicaltrials
@onclive.bsky.social📈 The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC. @ascocancer.bsky.social #ASCO26 #lcsm #oncology
More insights ➡️: www.onclive.com/view/tegaviv...
@onclive.bsky.socialResponses to ADC TUB-040 did not differ by NaPi2b expression level in platinum-resistant ovarian cancer, supporting a biomarker-unrestricted development path, according to Toon Van Gorp, MD, PhD. @ascocancer.bsky.social #ASCO26 #gyncsm #oncology
More insights ➡️: www.onclive.com/view/napista...
@onclive.bsky.socialWATCH: Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. @ascocancer.bsky.social #ASCO26 #gyncsm #oncology
Full video ➡️: www.onclive.com/view/dr-gilb...
@alliance-org.bsky.socialDiscover the latest advances in breast, lung & prostate cancer care! Join the Alliance for a free public webinar on Oct 1 featuring leading researchers & patient advocates sharing key findings from #ASCO26. Register now: bit.ly/Alliance-Webinar-Oct26 #clinicaltrials
@ipharmaservices.bsky.social@ipharmaservices.bsky.socialA $GSK adquire engajador de células T triespecífico da Chimagen por até $750M contra #MielomaMúltiplo. Fase 1 prevista para 2027: www.ipharmacenter.com/post/pharmac... #Câncer #Oncologia #Farmacêutica #OncoAlert #ASCO26
@ipharmaservices.bsky.social$GSK 斥资高达7.5亿美元收购 Chimagen 的三特异性T细胞接合器，针对 #多发性骨髓瘤，预计2027年进入一期临床：https://www.ipharmacenter.com/post/pharmaceutical-healthcare-deals-acquisitions-2026-ipharmacenter #癌症 #肿瘤学 #制药 #OncoAlert #ASCO26
@ipharmaservices.bsky.social$GSK erwirbt trispezifischen T-Zell-Engager von Chimagen für bis zu $750M gegen #MultiplesMyelom. Phase 1 für 2027 geplant: www.ipharmacenter.com/post/pharmac... #Krebs #Onkologie #Pharmazeutik #OncoAlert #ASCO26
@ipharmaservices.bsky.social$GSK acquiert un engageur de lymphocytes T trispécifique chez Chimagen pour $750M max ciblant le #MyélomeMultiple. Phase 1 en 2027: www.ipharmacenter.com/post/pharmac... #Cancer #Oncologie #Pharmaceutique #OncoAlert #ASCO26
@ipharmaservices.bsky.social$GSK adquiere un activador de células T triespecífico de Chimagen por hasta $750M contra el #MielomaMúltiple. Fase 1 prevista para 2027: www.ipharmacenter.com/post/pharmac... #Cáncer #Oncología #Farmacéutica #OncoAlert #ASCO26